Skip to main content
Livermore
Livermore
ZHEN

Affinity Asset Advisors, LLC

SEC CIK
0001773195
Latest filing
Aug 13, 2026

Holdings in Q3 2025

Holdings as of Sep 30, 2025, filed Nov 13, 2025. Long positions only; changes compare share counts with Q2 2025.

Institution overview
Positions
86
+9 vs. Q2 2025
Portfolio value
$1.07B
+$398.5M (+58.9%) vs. Q2 2025
Filed
Nov 13, 2025
SEC
Holdings of Affinity Asset Advisors, LLC in Q3 2025
SecurityClassSharesValue% of portfolioShare changeActionHistory
VRNAVerona Pharma plcSPONSORED ADS625,000$66.7M6.2%+15,000+2.5%AddedHistory
INSMINSMED IncCOM PAR $.01450,000$64.8M6.0%−25,000−5.3%ReducedHistory
SPYSPDR S&P 500 ETF TrustETF84,490$56.3M5.2%+84,490NewHistory
XENEXenon Pharmaceuticals Inc.COM1,400,000$56.2M5.2%+300,000+27.3%AddedHistory
MDGLMadrigal Pharmaceuticals, Inc.COM115,000$52.7M4.9%+35,000+43.8%AddedHistory
APGEApogee Therapeutics, Inc.COM1,173,426$46.6M4.3%+481,527+69.6%AddedHistory
ACLXArcellx, Inc.COMMON STOCK500,000$41.0M3.8%+5,000+1.0%AddedHistory
ALKSAlkermes plc.SHS1,250,000$37.5M3.5%+250,000+25.0%AddedHistory
NUVLNuvalent, Inc.COM384,417$33.2M3.1%−30,583−7.4%ReducedHistory
ABVXAbivax S.A.SPONSORED ADS360,000$30.6M2.8%+260,000+260.0%AddedHistory
MLYSMineralys Therapeutics, Inc.COM750,000$28.4M2.6%−150,000−16.7%ReducedHistory
TEVATeva Pharmaceutical Industries LtdSPONSORED ADS1,400,000$28.3M2.6%00.0%UnchangedHistory
MRUSMerus N.V.COM285,769$26.9M2.5%+215,769+308.2%AddedHistory
CNTACentessa Pharmaceuticals plcSPONSORED ADS1,107,162$26.8M2.5%+207,000+23.0%AddedHistory
LXEOLexeo Therapeutics, Inc.COM3,870,527$25.7M2.4%+281,172+7.8%AddedHistory
TRVITrevi Therapeutics, Inc.COM2,800,000$25.6M2.4%+265,942+10.5%AddedHistory
SYRESpyre Therapeutics, Inc.COM NEW1,419,299$23.8M2.2%+812,621+133.9%AddedHistory
RZLTRezolute, Inc.COM NEW2,100,000$19.7M1.8%−100,000−4.5%ReducedHistory
CYTKCytokinetics IncCOM NEW350,000$19.2M1.8%+350,000NewHistory
ORKAOruka Therapeutics, Inc.COM959,180$18.4M1.7%+355,701+58.9%AddedHistory
QUREuniQure N.V.SHS300,000$17.5M1.6%+165,000+122.2%AddedHistory
WVEWave Life Sciences, Inc.SHS2,100,000$15.4M1.4%+99,692+5.0%AddedHistory
PTGXProtagonist Therapeutics, IncCOM220,600$14.7M1.4%−219,400−49.9%ReducedHistory
SLNOSoleno Therapeutics IncCOM200,000$13.5M1.3%+200,000NewHistory
AVTXAvalo Therapeutics, Inc.COM NEW1,006,217$12.8M1.2%+398,345+65.5%AddedHistory
ESTAEstablishment Labs Holdings Inc.COM310,000$12.7M1.2%−24,863−7.4%ReducedHistory
Karyopharm Therapeutics Inc.48576UAA4NOTE 3.000%10/1–$12.5M1.2%–––
VTYXVentyx Biosciences, Inc.COM3,924,415$12.2M1.1%−611,767−13.5%ReducedHistory
ROIVRoivant Sciences Ltd.SHS800,000$12.1M1.1%+400,000+100.0%AddedHistory
TVTXTravere Therapeutics, Inc.COM500,000$11.9M1.1%−470,000−48.5%ReducedHistory
DNTHDianthus Therapeutics, Inc.COM262,100$10.3M1.0%+262,100NewHistory
TSHATaysha Gene Therapies, Inc.COM SHS3,000,000$9.81M0.9%+2,800,000+1,400.0%AddedHistory
ERASErasca, Inc.COM4,285,787$9.34M0.9%+200,000+4.9%AddedHistory
NRIXNurix Therapeutics, Inc.COM967,620$8.94M0.8%00.0%UnchangedHistory
VERAVera Therapeutics, Inc.CL A303,330$8.81M0.8%−241,670−44.3%ReducedHistory
ELVNEnliven Therapeutics, Inc.COM400,000$8.19M0.8%00.0%UnchangedHistory
Travere Therapeutics, Inc.89422GAA5NOTE 2.250% 3/0–$7.93M0.7%–––
NAMSNewAmsterdam Pharma Co N.V.ORDINARY SHARES275,000$7.82M0.7%00.0%UnchangedHistory
CLDXCelldex Therapeutics, Inc.COM NEW300,000$7.76M0.7%+300,000NewHistory
PRQRProQR Therapeutics N.V.SHS EURO3,600,000$7.67M0.7%+100,488+2.9%AddedHistory
TARSTarsus Pharmaceuticals, Inc.COM125,000$7.43M0.7%+125,000NewHistory
AKBAAkebia Therapeutics, Inc.COM2,450,000$6.69M0.6%+500,000+25.6%AddedHistory
MNPRMonopar TherapeuticsCOM NEW79,483$6.49M0.6%+11,983+17.8%AddedHistory
ZURAZura Bio LtdCLASS A ORD SHS1,274,351$5.52M0.5%+1,051,016+470.6%AddedHistory
VRDNViridian Therapeutics, Inc.COM250,000$5.39M0.5%−140,000−35.9%ReducedHistory
SVRASavara IncCOM1,500,000$5.36M0.5%+1,000,000+200.0%AddedHistory
IMVTImmunovant, Inc.COM300,000$4.84M0.4%+300,000NewHistory
Omeros Corp682143AK8NOTE 9.500% 6/1–$4.71M0.4%–––
RVMDRevolution Medicines, Inc.COM100,000$4.67M0.4%+100,000NewHistory
PCVXVaxcyte, Inc.COM125,000$4.50M0.4%00.0%UnchangedHistory
NAMSWNewAmsterdam Pharma Co N.V.*W EXP 11/22/202245,000$4.19M0.4%00.0%UnchangedHistory
Celcuity Inc.15102KAA8NOTE 2.750% 8/0–$4.00M0.4%–New–
FRNMFreenome, Inc.CL A ORD SHS350,000$3.76M0.3%00.0%UnchangedHistory
INSPInspire Medical Systems, Inc.COM50,000$3.71M0.3%+50,000NewHistory
OVIDOvid Therapeutics Inc.COM2,650,000$3.44M0.3%+1,982,484+297.0%AddedHistory
BBIOBridgeBio Pharma, Inc.COM65,000$3.38M0.3%−85,000−56.7%ReducedHistory
JAZZJazz Pharmaceuticals plcSHS USD25,000$3.29M0.3%00.0%UnchangedHistory
CRNXCrinetics Pharmaceuticals, Inc.COM75,000$3.12M0.3%−77,252−50.7%ReducedHistory
MBXMBX Biosciences, Inc.COM165,000$2.89M0.3%+165,000NewHistory
AUTLAutolus Therapeutics plcSPON ADS1,750,000$2.85M0.3%−1,295,000−42.5%ReducedHistory
OCULOcular Therapeutix, IncCOM239,000$2.79M0.3%+239,000NewHistory
OACCUOaktree Acquisition Corp. III Life SciencesUNIT 10/04/2029250,000$2.66M0.2%00.0%UnchangedHistory
CLYMClimb Bio, Inc.COM1,300,000$2.61M0.2%−200,000−13.3%ReducedHistory
OLMAOlema Pharmaceuticals, Inc.COM250,000$2.45M0.2%00.0%UnchangedHistory
SGMTSagimet Biosciences Inc.COM SER A350,000$2.40M0.2%+350,000NewHistory
ATXSAstria Therapeutics, Inc.COM300,000$2.18M0.2%00.0%UnchangedHistory
UTHRUnited Therapeutics CorpCOM5,000$2.10M0.2%+5,000NewHistory
GERNGeron CorpCOM1,500,000$2.06M0.2%00.0%UnchangedHistory
AVRAnteris Technologies Global Corp.COM450,000$2.02M0.2%+25,000+5.9%AddedHistory
OBIOOrchestra BioMed Holdings, Inc.COM727,272$1.80M0.2%+727,272NewHistory
EPRXEupraxia Pharmaceuticals Inc.COM300,000$1.77M0.2%+300,000NewHistory
CGEMCullinan Therapeutics, Inc.COM263,817$1.56M0.1%00.0%UnchangedHistory
MISTMilestone Pharmaceuticals Inc.COM666,666$1.33M0.1%+666,666NewHistory
CMPSCOMPASS Pathways plcSPONSORED ADS200,000$1.15M0.1%+200,000NewHistory
NXTCNextCure, Inc.COM NEW191,882$1.12M0.1%00.0%UnchangedConverted for a 1-for-12 splitHistory
CATXPerspective Therapeutics, Inc.COM NEW300,000$1.03M0.1%−750,000−71.4%ReducedHistory
STROSutro Biopharma, Inc.COM752,722$653.7K0.1%00.0%UnchangedHistory
JBIOJade Biosciences, Inc.COM NEW65,317$563.7K0.1%00.0%UnchangedHistory
ENGNenGene Therapeutics Inc.COM77,000$525.9K<0.1%00.0%UnchangedHistory
CNTXContext Therapeutics Inc.COM402,653$390.1K<0.1%−115,372−22.3%ReducedHistory
RPTXRepare Therapeutics Inc.COM200,000$352.0K<0.1%00.0%UnchangedHistory
CBIOCrescent Biopharma, Inc.COM17,998$214.0K<0.1%−262,033−93.6%ReducedHistory
ADGMAdagio Medical Holdings, Inc.COM80,000$155.2K<0.1%00.0%UnchangedHistory
QTTBQ32 Bio Inc.COM27,777$55.0K<0.1%00.0%UnchangedHistory
SPRYARS Pharmaceuticals, Inc.COM2,500$25.1K<0.1%+2,500NewHistory
Rocket Pharmaceuticals, Inc.77313F114*W EXP 09/02/20275,000$2.99K<0.1%00.0%Unchanged–

Options (9)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Affinity Asset Advisors, LLC in Q3 2025
SecurityClassPutsCalls
INSMINSMED IncCOM PAR $.01–$29.5M
EXELExelixis, Inc.COM$14.5M$6.20M
SMMTSummit Therapeutics Inc.COM$7.23M–
NTLAIntellia Therapeutics, Inc.COM–$5.18M
OMEROmeros CorpCOM$4.65M–
OLMAOlema Pharmaceuticals, Inc.COM–$2.45M
ATYRaTYR PHARMA INCCOM NEW$1.51M–
KPTIKaryopharm Therapeutics Inc.COM NEW–$1.03M
ABUSArbutus Biopharma CorpCOM–$960.2K

Sold out since Q2 2025 (10)

Positions held at the end of Q2 2025 that are gone from this filing.

Positions of Affinity Asset Advisors, LLC sold out since Q2 2025
SecurityClassShares in Q2 2025Value in Q2 2025% of portfolio in Q2 2025History
BPMCBlueprint Medicines CorpCOM250,000$32.0M4.7%History
INZYInozyme Pharma, Inc.COM1,749,359$7.00M1.0%History
AXSMAxsome Therapeutics, Inc.COM50,000$5.22M0.8%History
RAPPRapport Therapeutics, Inc.COM199,643$2.27M0.3%History
THRDThird Harmonic Bio, Inc.COM370,000$2.01M0.3%History
NKTXNkarta, Inc.COM800,000$1.33M0.2%History
MIRMMirum Pharmaceuticals, Inc.COM24,692$1.26M0.2%History
OKUROnKure Therapeutics, Inc.COM CL A347,990$831.7K0.1%History
RADXRadiopharm Theranostics LtdSPONSORED ADS35,635$166.1K<0.1%History
Immatics N.V.N44445117*W EXP 07/01/202187,204$112<0.1%–